RCUS
Arcus Biosciences Inc

1,788
Mkt Cap
$2.75B
Volume
1.17M
52W High
$26.40
52W Low
$6.50
PE Ratio
-6.66
RCUS Fundamentals
Price
$21.97
Prev Close
$22.70
Open
$22.71
50D MA
$21.66
Beta
1.48
Avg. Volume
1.07M
EPS (Annual)
-$3.29
P/B
4.36
Rev/Employee
$410,981.70
$1,776.34
Loading...
Loading...
News
all
press releases
WINTON GROUP Ltd Purchases Shares of 92,229 Arcus Biosciences, Inc. $RCUS
WINTON GROUP Ltd acquired a new position in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and...
Business Wire·6d ago
News Placeholder
Citigroup Raises Arcus Biosciences (NYSE:RCUS) Price Target to $45.00
Citigroup boosted their target price on shares of Arcus Biosciences from $44.00 to $45.00 and gave the stock a "buy" rating in a research report on Thursday...
MarketBeat·10d ago
News Placeholder
Arcus Biosciences (NYSE:RCUS) Stock Price Expected to Rise, Leerink Partners Analyst Says
Leerink Partners upped their price target on shares of Arcus Biosciences from $36.00 to $49.00 and gave the company an "outperform" rating in a research note on Monday...
MarketBeat·13d ago
News Placeholder
Arcus Biosciences (NYSE:RCUS) Shares Up 9.5% - Here's What Happened
Arcus Biosciences (NYSE:RCUS) Stock Price Up 9.5% - Time to Buy...
MarketBeat·13d ago
News Placeholder
Arcus Biosciences (NYSE:RCUS) Given "Buy" Rating at HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $32.00 price target on shares of Arcus Biosciences in a research report on Monday...
MarketBeat·13d ago
News Placeholder
HC Wainwright Brokers Increase Earnings Estimates for RCUS
Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Investment analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for shares of Arcus Biosciences in a note issued to...
MarketBeat·14d ago
News Placeholder
Arcus Biosciences Q4 Earnings Call Highlights
Arcus Biosciences (NYSE:RCUS) used its fourth-quarter and full-year 2025 earnings call to highlight updated clinical data for its lead oncology program, casdatifan, and to outline near-term plans for...
MarketBeat·15d ago
News Placeholder
Wall Street Zen Upgrades Arcus Biosciences (NYSE:RCUS) to Hold
Wall Street Zen raised Arcus Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·16d ago
News Placeholder
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of "Moderate Buy" from Brokerages
Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) has been given an average rating of "Moderate Buy" by the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. One...
MarketBeat·16d ago
<
1
2
...
>

Latest RCUS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.